FHL1 and neoplasm: Meanwhile, the ataxia telangiectasia and Rad3-related protein (ATR) inhibitor VE-822 exhibits LUAD suppression through a novel OTUD1-FHL1 axis, inhibiting tumor growth both in vitro and in vivo (50).